Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 5961342, 18 pages
Review Article

Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide?

1Division de Physiopathologie Clinique, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1005 Lausanne, Switzerland
2Service de Médecine Intensive Adulte, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1005 Lausanne, Switzerland

Received 18 June 2015; Revised 8 September 2015; Accepted 8 October 2015

Academic Editor: Kequan Guo

Copyright © 2016 Nathalie Rosenblatt-Velin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The discovery that stem cells isolated from different organs have the ability to differentiate into mature beating cardiomyocytes has fostered considerable interest in developing cellular regenerative therapies to treat cardiac diseases associated with the loss of viable myocardium. Clinical studies evaluating the potential of stem cells (from heart, blood, bone marrow, skeletal muscle, and fat) to regenerate the myocardium and improve its functional status indicated that although the method appeared generally safe, its overall efficacy has remained modest. Several issues raised by these studies were notably related to the nature and number of injected cells, as well as the route and timing of their administration, to cite only a few. Besides the direct administration of cardiac precursor cells, a distinct approach to cardiac regeneration could be based upon the stimulation of the heart’s natural ability to regenerate, using pharmacological approaches. Indeed, differentiation and/or proliferation of cardiac precursor cells is controlled by various endogenous mediators, such as growth factors and cytokines, which could thus be used as pharmacological agents to promote regeneration. To illustrate such approach, we present recent results showing that the exogenous administration of the natriuretic peptide BNP triggers “endogenous” cardiac regeneration, following experimental myocardial infarction.